Project Grant HT94252410722

The National Cancer Institute awarded a 5-year, $632,906 Project Grant to Tulane University under the Cancer Biology Research federal grant program (CFDA 93.396). The grant aims to elucidate a novel role for the androgen receptor (AR) in promoting prostate cancer progression and therapeutic resistance through its RNA-binding activity. Specifically, the research will investigate how AR binds to and regulates the expression of key splicing factors, leading to efficient splicing and expression of...

This $157,044 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) is supporting research to investigate the molecular mechanisms underlying the interactions between the intrinsically disordered protein ABI1 and the androgen receptor (AR) in prostate cancer. The Research Foundation for the State University of New York, operating as Upstate Medical Center, is the awardee conducting this 28-month project. The research aims to: 1) elucidate the...

The National Cancer Institute (NCI) awarded a $535,334 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Albert Einstein College of Medicine to conduct research on the non-autonomous role of androgen signaling in prostate tumorigenesis. The project aims to investigate how androgen receptor (AR) activation in prostatic stromal cells, specifically those expressing the GLI1 transcription factor, can promote prostate epithelial oncogenesis and tumor development through paracrine signaling...

This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) provides $245,472 to Duke University to study the role of the androgen receptor (AR) in hepatocellular carcinoma (HCC), the third leading cause of cancer death in the U.S. The project aims to: 1) measure the effect of AR signaling on the oncogenic traits of HCC models, 2) define the transcriptional profile of AR in HCC, and 3) determine the therapeutic potential of AR inhibition in...

This $564,543 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393). The grant supports research at the Weill Medical College of Cornell University to investigate how the androgen receptor (AR) governs normal, growth-suppressive gene expression in prostate cells, and how this program becomes hijacked to drive oncogenic transcription in prostate cancer. The research aims to determine if the normal,...

The University of Pennsylvania received a $371,719 Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) to conduct research towards characterizing epigenetic targets in prostate cancer. The 5-year project, awarded on March 1, 2025, aims to identify, characterize, and therapeutically target co-factors and chromatin-associated proteins involved in the androgen receptor signaling pathway in prostate cancer. Specifically, the research will...

The University of Miami was awarded a $538,553 federal Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to conduct longitudinal research on the use of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of treatment outcomes for prostate cancer patients receiving radiotherapy and androgen deprivation therapy (ADT). The goal of the 5-year research project is to define the role of mpMRI and...

The National Cancer Institute awarded a $571,271 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston. The goal of this 5-year research project is to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer, an aggressive form of the disease with limited treatment options. The project will explore using a small molecule drug conjugate that targets the prostate-specific membrane...

This federal Project Grant award of $2,579,971.00, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to investigate the molecular drivers and therapeutic susceptibilities of lineage state transitions in metastatic prostate cancer. The 5-year project, awarded to the University of Wisconsin - Madison, aims to study the regulation of the androgen receptor transcriptional state in distinct tumor niches, evaluate the role of genomic...

The University of Maryland, Baltimore will conduct research on the regulation of cellular plasticity by androgen receptor splicing variants in prostate cancer under a three-year, $1,390,500 Project Grant from the Defense Health Agency. The grant supports the Military Medical Research and Development program, which aims to transform military and public health through innovative medical research solutions for battlefield wounds and illnesses. The University will investigate medical solutions for...